Date: 2016-05-20
Type of information: Treatment of the first patient
phase: 1
Announcement: treatment of the first patient
Company: Janssen Research & Development, a J&J company (USA - NJ)
Product: JNJ-61178104
Action
mechanism: bispecific antibody.
Disease:
Therapeutic area:
Country: Belgium
Trial
details: This phase 1, randomized, double-blind, placebo-controlled, single ascending dose, interventional study will assess the safety, tolerability, pharmacokinetics (PK) and immunogenicity of JNJ-61178104 following a single ascending Intravenous (IV) dose administration and a single Subcutaneous (SC) dose administration in healthy participants. (NCT02758392)
Latest
news: * On May 20, 2016, Genmab announced that the first participants have been dosed in a clinical study of a DuoBody® bispecific antibody under Genmab’s DuoBody technology platform collaboration with Janssen Biotech. The Phase I study investigates the human bispecific antibody JNJ-61178104, which is directed to two inflammatory disease targets, for potential use in treating autoimmune disorders. Genmab will receive a $2 million milestone payment for the progress in the study.
